tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: CTI BioPharma (CTIC) and Turning Point Therapeutics (TPTX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on CTI BioPharma (CTICResearch Report) and Turning Point Therapeutics (TPTXResearch Report).

CTI BioPharma (CTIC)

Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on CTI BioPharma yesterday and set a price target of $6.50. The company’s shares closed last Monday at $5.16.

According to TipRanks.com, Burnett has 0 stars on 0-5 stars ranking scale with an average return of -23.2% and a 18.9% success rate. Burnett covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Crispr Therapeutics AG, and eFFECTOR Therapeutics.

Currently, the analyst consensus on CTI BioPharma is a Strong Buy with an average price target of $8.50, representing a 61.3% upside. In a report issued on June 4, Brookline Capital Markets also maintained a Buy rating on the stock with a $12.00 price target.

See the top stocks recommended by analysts >>

Turning Point Therapeutics (TPTX)

In a report issued on June 10, Bradley Canino from Stifel Nicolaus maintained a Hold rating on Turning Point Therapeutics, with a price target of $76.00. The company’s shares closed last Monday at $74.28, close to its 52-week high of $83.06.

According to TipRanks.com, Canino ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -49.7% and a 2.8% success rate. Canino covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Zentalis Pharmaceuticals, and Arvinas Holding Company.

Currently, the analyst consensus on Turning Point Therapeutics is a Hold with an average price target of $73.43, implying a -1.0% downside from current levels. In a report issued on June 3, Wedbush also downgraded the stock to Hold with a $76.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CTIC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed